key: cord-0773769-1myh24ab
authors: Whittle, Jessica S.; Pavlov, Ivan; Sacchetti, Alfred D.; Atwood, Charles; Rosenberg, Mark S.
title: Respiratory support for adult patients with COVID‐19
date: 2020-04-13
journal: J Am Coll Emerg Physicians Open
DOI: 10.1002/emp2.12071
sha: ed72b1768af79acb915279c8776907650f97db26
doc_id: 773769
cord_uid: 1myh24ab

The COVID‐19 pandemic is creating unique strains on the healthcare system. While only a small percentage of patients require mechanical ventilation and ICU care, the enormous size of the populations affected means that these critical resources may become limited. A number of non‐invasive options exist to avert mechanical ventilation and ICU admission. This is a clinical review of these options and their applicability in adult COVID‐19 patients. Summary recommendations include: (1) Avoid nebulized therapies. Consider metered dose inhaler alternatives. (2) Provide supplemental oxygen following usual treatment principles for hypoxic respiratory failure. Maintain awareness of the aerosol‐generating potential of all devices, including nasal cannulas, simple face masks, and venturi masks. Use non‐rebreather masks when possible. Be attentive to aerosol generation and the use of personal protective equipment. (3) High flow nasal oxygen is preferred for patients with higher oxygen support requirements. Non‐invasive positive pressure ventilation may be associated with higher risk of nosocomial transmission. If used, measures special precautions should be used reduce aerosol formation. (4) Early intubation/mechanical ventilation may be prudent for patients deemed likely to progress to critical illness, multi‐organ failure, or acute respiratory distress syndrome (ARDS).

critically ill COVID-19 cases has exceeded the intensive care unit (ICU) capacity of affected regions, and in NYC, critical illness from COVID-19 has already far exceeded existing ICU capacity. In the US, critical care capacity was limited even before the COVID-19 pandemic with over one-third of patients having to wait 6 hours or more for transfer to an ICU. 4, 5 A number of non-invasive options exist to support COVID-19 patients with mild or moderate respiratory distress and may reduce the numbers of patients requiring intubation, mechanical ventilation, and ICU admission in some severely ill patients. 19 However, all forms of supplemental oxygenation and respiratory support may potentially aerosolize respiratory pathogens. [6] [7] [8] Selection of respiratory support for patients affected by COVID-19 must balance the clinical benefit of the intervention against the risks of nosocomial spread. Complicating this goal is that mitigation of aerosolization by early endotracheal intubation commits to the prolonged use of an ICU bed and mechanical ventilator, which may not be available in the context of a pandemic. Therefore, management of the COVID-19-associated respiratory failure must consider the full spectrum of invasive and non-invasive ventilation options.

In this clinical review, we summarize the options and provide practical recommendations for respiratory support in COVID-19 patients.

Any patient suspected of having COVID-19 disease should be managed in a negative pressure room when possible. This is particularly true for patients requiring any form of supplemental oxygen therapy. Staff treating the patient should use maximum PPEs with N-95 masks and eye protection. When no negative pressure room is available, a closed room may be the only option. Simple measures such as placing a surgical mask over all patients in the ED may be helpful in mitigating the pathogenic spread. 

Simple masks provide supplemental oxygen with flow rates up to approximately 5-10 L/min. Respiratory rate and exhalation are controlled by the patient and these individually affect the actual FiO 2 delivered. Oxygen supplementation via simple mask is only marginally greater than that of nasal cannula. High fidelity human mannequin model studies showed the maximum exhaled dispersion distance using a simple mask at 10 L/min was 40 cm (Figure 1 ). 12

Supplemental oxygen by venturi mask allows more precise oxygen delivery. FiO 2 is delivered in discrete levels, typically between 24% and 60% oxygen. The mask uses an air/oxygen entrainment device (venturi)

to more precisely mix air and oxygen. Each FiO 2 level is achieved with a "snap-on" venturi, which specifies the oxygen flow rate to achieve the selected FiO 2 . Oxygen flow rates are specified, and typically vary from 2 to 15 L/min. In studies using a high fidelity human mannequin model, the maximum exhaled dispersion distance varied from 33 cm at FiO 2 40%, to 40 cm at FiO 2 24% (Figure 1 ). 12

Non-rebreather masks (NRBs) offer a safe way to provide supplemental oxygen to COVID-19 patients as the mask helps to limit the dispersion of droplets. NRB masks can provide supplemental oxygen up to a level of approximately 90% at flow rates approaching 15 L/min. 13 To prevent hypercapnia, the reservoir bag must remain inflated at all times; this requires flow rates of at least 8-10 L/min. 14 High fidelity human mannequin studies demonstrate that the maximum exhaled dispersion distance at 10 L/min is <10 cm, suggesting that this modality generates the least dispersed aerosols ( Figure 1 ). 12 and decreases breathing frequency and work of breathing. 20 The use of HFNO was associated with lower mortality in hypoxemic respiratory failure. 21 Compared to conventional oxygen therapy, HFNO is associated with decreased risk of subsequent intubation (relative risk

[RR] 0.85, 95% confidence interval [CI] 0.74-0.99) 22 and need for ICU admission. 23, 24 Initial concern existed on the risk of aerosolization with HFNO leading some to recommend avoiding use of this modality. However, the degree of aerosolization has been shown to minimal with these devices, and it is now recommended as the oxygenation therapy of choice in patients with respiratory distress. Guidelines from the WHO, 2 the Italian Thoracic Society, 15 the Respiratory Care Committee of the Chinese Thoracic Society, 16 The Australian and New Zealand Intensive Care

Society, 17 Because of their construction, HF/HV systems demonstrate favorable safety profiles as an AGP. A high-fidelity mannequin study demonstrated that even at the highest setting of 60 L/min, exhaled air dispersion was 17 cm in a healthy lung scenario and only 4.8 cm in a severely diseased lung scenario. 25 The authors cautioned that if the connection from the tubing to the nasal cannula becomes dis-connected there might be a risk of lateral dispersion of oxygen and pathogens. 25 Some guidelines recommend placement of a surgical mask over patients being treated with high flow therapies as a secondary safety measure. 18 High fidelity human mannequin simulation studies show surgical masks do, in fact, reduce exhaled air dispersion ( Figure 1 ). 26 If HFNO oxygen therapy is used, medical staff should use airborne protection, and the patient should be treated in a negative pressure room, if available. 2, 17 There is no currently published evidence that HFNO is a risk factor for nosocomial transmission of respiratory pathogens. [27] [28] [29] [30] During the 2003 Toronto SARS-CoV outbreak, HFNO was not found to be a risk factor for transmission to healthcare workers. 29 This is in contrast with endotracheal intubation, which was strongly associated with transmission to healthcare workers during the SARS epidemic. 29 For the treatment of pneumonia, HFNO was associated with reduced mortality compared to NIPPV. 21 work was performed inside a negative pressure room (Figure 1) . 11, 12, 25 Helmet mask BiPAP is unique and a similar mannequin study showed that it is safer than other models. The maximal measured dispersal distance from the helmet-neck interface was 2.7 cm when an air cushion was in place around the neck (missing air cushions cause severe dispersion). 11 The use of CPAP or BiPAP is debated in patients with COVID- In the same studies, high flow oxygen masks (defined as flow rates >6 L/min) and mechanical ventilation were not associated with nosocomial spread. 40, 41 These data may be of particular relevance to the COVID-19 outbreak, where 3019 cases have already been reported in healthcare workers including 5 deaths as of February 11, 2020. 42 It is unknown if any of these were associated with the use of any particular respiratory treatment.

These conflicting data suggest that BiPAP should be considered cautiously. Closed circuit systems with appropriate filters in place are important, as are well-fitting masks and the absence of facial hair on the patient, allowing for tight seals. Helmet BiPAP with an air cushion in place around the neck is safe and should be used if available. All other forms have been associated with higher dispersal distances than high flow oxygen systems and concern for nosocomial and healthcare provider infection. Properly trained personnel are also crucial.

Nebulizer treatments should be avoided in the care of patients with COVID-19. Jet nebulizers were largely responsible for the spread of SARS in a hospital ward in China in 2003. 12 The safety profile regarding APGs for these devices are extremely poor. Modeling with human patient simulation shows that dispersion of particles could be measured beyond 0.8 m when flow rates mimicking severe lung injury were used (oxygen consumption of 500 mL/min, lung compliance 10 mL/cmH 2 O) ( Figure 1 ). 43 Jet nebulized therapies are possibly some of the highest risk events

for nosocomial viral transmission and should only be performed when absolutely necessary in negative pressure environments with highly trained personnel. Some high flow/high velocity systems and closed positive pressure systems have capabilities to add nebulized medications without an increased risk of particle dispersal.

Alternatives to nebulizer therapies include use of metered dose inhalers, or nebulized therapies performed in an adapted oral/nasal mask. 44 While estimates vary due to methodology, 4-6 puffs of a metered dose inhaler is the dose equivalent to a 2.5 mg nebulized dose of albuterol. 45 Placement of a viral filter inline with a nebulizer likely decrease the risk for nosocomial or healthcare worker infection but to our knowledge, no studies have directly measured this effect.

Mechanical ventilation through an endotracheal tube may be neces- include, but are not limited to: (1) need of vasopressor support, 30, 34 (2) persistently high respiratory rate, (3) persistent thoracoabdominal asynchrony, 35 or (4) low ROX index. 36 Consider expert opinion in indeterminate cases. When in doubt, err on the side of early intubation If clinical findings are consistent with ARDS, hemodynamic instability, altered mental status, or severe hypoxia, proceed directly to endotracheal intubation and mechanical ventilation, unless not available or not desired by the patient.

NIPPV should only be used if helmet masks are available, or if high flow oxygen systems options are not available (summary in Figure 2 ).

The COVID-19 pandemic requires a more comprehensive risk-benefit analysis with deciding the modality of respiratory support for patients.

The risks for healthcare worker infection, nosocomial spread, availability of resources, and clinical spectrum of disease must all be considered.

Jessica S. Whittle has served as a consultant to Vapotherm, Inc., within the last 3 years for the development of educational materials. All compensation totaled less than $1000. Ivan Pavlov has been a speaker for Fisher-Pakyel within the last 3 years. All compensation was paid to the charitable foundation at the hospital where he works and he did not personally receive any compensation. Alfred D. Sacchetti, Charles

Atwood, and Mark S. Rosenberg have no disclosures.

Jessica S. Whittle MD PhD https://orcid.org/0000-0003-3177-8934

Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures

Clinical management of severe acute respiratory infection when Novel coronavirus (2019-nCoV) infection is suspected: Interim Guidance

Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand

National growth in intensive care unit admissions from emergency departments in the United States from

Increasing critical care admissions from U.S. emergency departments

Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review

Guidance on infection prevention and control for COVID-19

HPSC. Aerosol Generating Procedures (AGPs)

COVID-19) in Healthcare Settings

Exhaled air dispersion during noninvasive ventilation via helmets and a total facemask

Aerosol dispersion during various respiratory therapies: a risk assessment model of nosocomial infection to health care workers

Delivery of high inspired oxygen by face mask

Carbon dioxide narcosis due to inappropriate oxygen delivery: a case report

Managing the Respiratory care of patients with COVID-19

Respiratory care committee of Chinese Thoracic S. [Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by

-19 Guidelines. Australian and New Zealand Intensive Care Society. Melbourne: ANZICS; 2020

Intensivmedizin und Notfallmedizin

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

High-flow nasal cannula oxygen therapy in adults: physiological benefits, indication, clinical benefits, and adverse effects

High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure

High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis

Efficacy of high-flow nasal cannula therapy in acute hypoxemic respiratory failure: decreased use of mechanical ventilation

Introducing high-flow nasal cannula oxygen therapy at the intermediate care unit: expanding the range of supportive pulmonary care

Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks

Exhaled air dispersion during coughing with and without wearing a surgical or N95 mask

Comparison of highflow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically ill pneumonia patients: a randomized controlled crossover trial

Assessment of the potential for pathogen dispersal during high-flow nasal therapy

Risk factors for SARS transmission from patients requiring intubation: a multicentre investigation in Toronto

High-flow nasal therapy in adults with severe acute respiratory infection: a cohort study in patients with 2009 influenza A/H1N1v

Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province

Clinical characteristics of coronavirus disease 2019 in China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists

Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study

An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy

Beyond low tidal volume ventilation: treatment adjuncts for severe respiratory failure in acute respiratory distress syndrome

Treatment for severe acute respiratory distress syndrome from COVID-19. The Lancet Respiratory Medicine

Effectiveness of noninvasive positive pressure ventilation in the treatment of acute respiratory failure in severe acute respiratory syndrome

Transmission of severe acute respiratory syndrome during intubation and mechanical ventilation

Why did outbreaks of severe acute respiratory syndrome occur in some hospital wards but not in others?

Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 Pneumonia in Wuhan, China

Critical care crisis and some recommendations during the COVID-19 epidemic in China

Nebulized Brochodilator Instead of MDI

Respiratory support for adult patients with COVID-19